Baidu
map

Sci Transl Med :新型凝胶可在性行为后防HIV病毒

2014-03-13 佚名 新华网

美国研究人员12日说,他们开发出一种新型阴道凝胶,从动物实验结果推测,即便在性行为3个小时后使用也可能保护女性不被艾滋病病毒感染。 美国疾病控制和预防中心研究人员当天在学术刊物《科学-转化医学》上报告说,新型凝胶包含抗逆转录病毒药物雷特格韦,可有效阻断艾滋病病毒的复制,这是因为艾滋病病毒感染细胞大约需要6个小时,从而为女性在性行为后用药提供了一个比较长的时间窗口。 研究人员使用与人类艾滋病病毒

美国研究人员12日说,他们开发出一种新型阴道凝胶,从动物实验结果推测,即便在性行为3个小时后使用也可能保护女性不被艾滋病病毒感染。

美国疾病控制和预防中心研究人员当天在学术刊物《科学-转化医学》上报告说,新型凝胶包含抗逆转录病毒药物雷特格韦,可有效阻断艾滋病病毒的复制,这是因为艾滋病病毒感染细胞大约需要6个小时,从而为女性在性行为后用药提供了一个比较长的时间窗口。

研究人员使用与人类艾滋病病毒相似的人猴嵌合免疫缺陷病毒(SHIV)攻击6只猕猴,然后在3个小时后使用新型凝胶,结果其中5只猕猴受到保护没有染上病毒。研究人员计划接下来开展更大规模的动物实验进一步验证新型凝胶的效果。

此前阴道凝胶一直被设计成在性行为发生前使用。研究人员表示,这让它们的使用范围受到限制,能在性行为后使用的凝胶会给予女性更多的掌控能力,相比前者更加实际、有效。

原始出处:

Charles Dobard, Sunita Sharma, Urvi M. Parikh, Rolieria West, Andrew Taylor, Amy Martin,Chou-Pong Pau, Debra L. Hanson, Jonathan Lipscomb, James Smith, Francis Novembre, Daria Hazuda,J. Gerardo Garcia-Lerma, and Walid Heneine. Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical IntegraseInhibitors. Sci Transl Med 12 March 2014 6:227ra35. DOI:10.1126/scitranslmed.3007701

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2067141, encodeId=c3ad206e14182, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Nov 15 03:57:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656604, encodeId=25281656604a0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Dec 27 14:57:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322346, encodeId=f955132234645, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412610, encodeId=5abb141261030, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460906, encodeId=48181460906d9, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606135, encodeId=40f5160613594, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2067141, encodeId=c3ad206e14182, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Nov 15 03:57:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656604, encodeId=25281656604a0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Dec 27 14:57:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322346, encodeId=f955132234645, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412610, encodeId=5abb141261030, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460906, encodeId=48181460906d9, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606135, encodeId=40f5160613594, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=)]
    2014-12-27 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=2067141, encodeId=c3ad206e14182, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Nov 15 03:57:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656604, encodeId=25281656604a0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Dec 27 14:57:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322346, encodeId=f955132234645, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412610, encodeId=5abb141261030, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460906, encodeId=48181460906d9, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606135, encodeId=40f5160613594, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=)]
    2014-03-15 xugc
  4. [GetPortalCommentsPageByObjectIdResponse(id=2067141, encodeId=c3ad206e14182, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Nov 15 03:57:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656604, encodeId=25281656604a0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Dec 27 14:57:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322346, encodeId=f955132234645, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412610, encodeId=5abb141261030, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460906, encodeId=48181460906d9, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606135, encodeId=40f5160613594, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2067141, encodeId=c3ad206e14182, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Nov 15 03:57:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656604, encodeId=25281656604a0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Dec 27 14:57:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322346, encodeId=f955132234645, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412610, encodeId=5abb141261030, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460906, encodeId=48181460906d9, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606135, encodeId=40f5160613594, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=)]
    2014-03-15 lishizhe
  6. [GetPortalCommentsPageByObjectIdResponse(id=2067141, encodeId=c3ad206e14182, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Nov 15 03:57:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656604, encodeId=25281656604a0, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Dec 27 14:57:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322346, encodeId=f955132234645, content=<a href='/topic/show?id=cde152e227a' target=_blank style='color:#2F92EE;'>#性行为#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52722, encryptionId=cde152e227a, topicName=性行为)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412610, encodeId=5abb141261030, content=<a href='/topic/show?id=32ec89220b' target=_blank style='color:#2F92EE;'>#HIV病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8922, encryptionId=32ec89220b, topicName=HIV病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa102876871, createdName=tigerlr99, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460906, encodeId=48181460906d9, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606135, encodeId=40f5160613594, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Mar 15 08:57:00 CST 2014, time=2014-03-15, status=1, ipAttribution=)]
    2014-03-15 zhaojie88

相关资讯

Nat Med:研究发现HIV长期藏匿之所

日前,来自麻省总医院与哈佛医学院等机构的研究人员发现 TSCM 细胞(T memory stem cell)可能是 HIV 病毒长期潜伏的藏身地,这些细胞有望成为未来 HIV 治疗的潜在靶点。相关研究论文刊登在了近期出版的《自然-医学》(Nature Medicine)杂志上。 目前, HIV 抗病毒药物能够抑制病毒的复制,允许患者相对健康地生活多年。不过, HIV 病毒仍然

HIV基因疗法取得重大进展

一项临床试验日前表明,一种基因编码技术对于人类而言是安全且有效的。这是研究人员第一次使用一种名为锌指核酸酶(ZFN)的酶瞄准并破坏了12名艾滋病病毒(HIV)携带者免疫细胞中的一种基因,从而增强了他们抵抗病毒的能力。该项研究成果发表在3月6日出版的《新英格兰医学杂志》上。 美国加利福尼亚州杜瓦迪市希望之城国家医学中心贝克曼研究所分子生物学家John Rossi说:“这是HIV基因

Science:何大一改变HIV预防的游戏规则

4日,著名美国华裔科学家何大一的研究团队报告说,他们开发出一种新型药物,将来人们只要打上一针,就有可能3个月不被艾滋病病毒感染。研究人员认为,使用这种药物可成为开发出艾滋病疫苗前的过渡方案。  这项研究当天在波士顿举行的一个艾滋病会议上公布,并已在美国《科学》(Science)杂志网站上在线发表。因发明艾滋病鸡尾酒疗法而闻名的何大一(David D. Ho)教授表示:“这项成果将会

默沙东doravirine用于初治HIV疗效显著

3月6日,默沙东(Merck & Co)在第21届逆转录病毒和机会性感染大会(CROI 2014)上公布了实验性HIV药物doravirine IIb期临床试验的积极数据。该项随机、双盲、剂量探索研究,在初治HIV成人感染者中开展,调查了4种剂量doravirine(25mg、50mg,75mg,100mg;每日一次)联合替诺福韦/恩曲他滨(tenofovir/emtricitabine;

NEJM:基因疗法首次降伏HIV(图)

一项临床试验日前表明,一种基因编码技术对于人类而言是安全且有效的。这是研究人员第一次使用一种名为锌指核酸酶(ZFN)的酶瞄准并破坏了12名艾滋病病毒(HIV)携带者免疫细胞中的一种基因,从而增强了他们抵抗病毒的能力。该项研究成果发表在3月6日出版的《新英格兰医学杂志》上。 美国加利福尼亚州杜瓦迪市希望之城国家医学中心贝克曼研究所分子生物学家John Rossi说:“这是H

葛兰素史克HIV新药Tivicay获欧盟批准

葛兰素史克(GSK)、辉瑞(Pfizer)、盐野义(Shionogi)共同成立的HIV/AIDS合资企业ViiV Healthcare 1月21日宣布,HIV新药Tivicay(dolutegravir,50mg片剂)获欧盟委员会(EC)批准,联合其他抗逆转录病毒药物用于HIV成人感染者和12岁以上青少年感染者的治疗。 Tivicay的获批,是基于4个关键性III期临床试验(SPRING-2、S

Baidu
map
Baidu
map
Baidu
map